How JBC sold its Soul to the Devil
All good things come to an end.
By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
All good things come to an end.
“There is no reason for an investigation into scientific misconduct and therefore it will not take place.”
“Whole cohorts of peer-reviewers have been trained to view all these mannerist stylings as what western blots should look like. […] It will be a challenge to convince them otherwise.” – Smut Clyde.
“…Dr. Hetz seems rather to regret that he did not have better tools for editing the figures, so that the undeclared interventions would have gone unnoticed.” – University of Chile investigative report.
“you can make a mistake once, but twice hmmmm I’d like to have my name removed from the potential revised version of this manuscript”, – Prof Guillemin.
Attack is the best form of defence. Especially when your commercial clinical research is tainted by preclinical Photoshop fraud.
“For the most competitive papers, an ultra-rapid review (by members of the Editorial Board) is necessary to publish them a few days after submission.”, Misha Blagosklonny, on how his journals became papermill fraud bonanza
An exclusive interview with Siladitya Bandyopadhyay, about bullying and research fraud in the Arati Ramesh lab at NCBS Bangalore.
Giorgio Zauli’s rectorship term ends. Will research fraud, media harassment and whistleblower persecution be a thing of the past at the University of Ferrara? Ma dai, basta cazzate.
Dead men don’t talk. A dead colleague, especially a foreigner, is a perfect scapegoat to blame for fake data in your papers. And in your own PhD thesis.









